Pathways and mechanisms of venetoclax resistance.

abstract：:This study reports on the cytogenetic features of a novel case of pediatric Burkitt-like lymphoma (BLL), that adds to the three published. Four groups of cytogenetic abnormalities were detected in the present case: (1) imbalances shared by most germinal center (GC) derived B-cell tumors including BLL (+1q, -6q, -8p, +...

journal_title：Leukemia & lymphoma

authors： Pezzolo A,Cinti R,Negri F,Parodi F,Garaventa A,Gambini C,Pistoia V

更新日期：2006-11-01 00:00:00

abstract：:To better define the incidence and nature of secondary chromosome anomalies in mantle cell lymphoma (MCL) carrying the t(11:14)/BCL1 rearrangement, cytogenetic and fluorescence in situ hybridization studies (FISH) were performed in 42 patients (39 classical histology, 3 blastoid variant), using 6q21, 9p21/p16, 13q14, ...

journal_title：Leukemia & lymphoma

authors： Bigoni R,Cuneo A,Milani R,Roberti MG,Bardi A,Rigolin GM,Cavazzini F,Agostini P,Castoldi G

更新日期：2001-02-01 00:00:00

abstract：:We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 month...

journal_title：Leukemia & lymphoma

authors： Chong EA,Svoboda J,Cherian S,Andreadis C,Downs LH,Zhuang H,Alavi A,Tsai DE,Schuster SJ

更新日期：2005-09-01 00:00:00

abstract：:We performed a phase II study of dexamethasone, ifosfamide, idarubicin and etoposide (DIZE) in patients with relapsed or refractory Hodgkin's (HL) and non-Hodgkin's lymphoma (NHL). The regimen consisted of dexamethasone (20 mg i.v. days 1-4), idarubicin (8 mg/m2 i.v. days 1+2), continuous infusion (c.i.) of ifosfamide...

journal_title：Leukemia & lymphoma

authors： Reiser M,Schnell R,Straub G,Borchmann P,Wilhelm M,Ubelacker R,Wörmann B,Münch R,Diehl V,Engert A

更新日期：1998-10-01 00:00:00

abstract：:A new Ph1-positive acute lymphoblastic leukemia cell line, designated as ALL/MIK, has been developed from a patient with Ph1-positive acute leukemia. The ALL/MIK cells showed an immunophenotype of common ALL with rearranged JH and Jk genes. The ALL/MIK cells showed no M-bcr rearrangement using Southern blot analysis w...

journal_title：Leukemia & lymphoma

authors： Higa T,Okabe M,Kunieda Y,Kodama S,Itaya T,Kurosawa M,Sakurada K,Maekawa I,Shoji M,Kasai M

更新日期：1994-01-01 00:00:00

abstract：:Natural killer (NK)/T cell lymphoma associated with hemophagocytic syndrome (NK/T-LAHS) is a rare and life-threatening disease. The clinical features and overall survival of NK/T cell and other T cell lymphomas associated with hemophagocytic syndrome remain uncertain. We retrospectively reviewed the clinical records o...

journal_title：Leukemia & lymphoma

authors： Han L,Li L,Wu J,Li X,Zhang L,Wang X,Fu X,Ma W,Sun Z,Zhang X,Chang Y,Guo S,Zhang M

更新日期：2014-09-01 00:00:00

abstract：:Several surveys have defined chronic lymphocytic leukemia (CLL) patients as a high-risk patient population for developing second neoplasms. As possible mechanisms underlying the increased risk of specific second malignancies in CLL patients the immunodeficiency associated with disease is generally proposed. As far as ...

journal_title：Leukemia & lymphoma

authors： Molica S

更新日期：2005-01-01 00:00:00

abstract：:To assess the efficacy of haploidentical hematopoietic stem cell transplantation (HSCT) in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH), we retrospectively analyzed 30 cases that presented at our institution. At the time of HSCT, 20 patients (66.7%) had achieved a resp...

journal_title：Leukemia & lymphoma

authors： Li Z,Wang Y,Wang J,Zhang J,Wang Z

更新日期：2018-01-01 00:00:00

abstract：:A retrospective clinico-pathological study was performed on 208 consecutively recruited patients (94 males, 114 females, median age 67 years) with idiopathic (primary) osteo-/ myelofibrosis (IMF). According to bone marrow histology (cellularity) as well as extent (semiquantitative grading) and quality (reticulin/colla...

journal_title：Leukemia & lymphoma

authors： Thiele J,Kvasnicka HM,Werden C,Zankovich R,Diehl V,Fischer R

更新日期：1996-07-01 00:00:00

abstract：:Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, an...

journal_title：Leukemia & lymphoma

authors： Sidiqi MH,Gertz MA

更新日期：2019-02-01 00:00:00

abstract：:Recent studies suggested that MYC and BCL2 protein co-expression is an independent indicator of poor prognosis in diffuse large B-cell lymphoma. However, the immunohistochemistry protocols for dual-expression staining and the scoring cut-offs vary by study. Sixty-nine cases of diffuse large B-cell lymphoma were evalua...

journal_title：Leukemia & lymphoma

authors： Clark Schneider KM,Banks PM,Collie AM,Lanigan CP,Manilich E,Durkin LM,Hill BT,Hsi ED

更新日期：2016-07-01 00:00:00

abstract：:Isochromosome 17q [i(17q)] is frequently observed in the blast crisis (BC) of chronic myelogenous leukemia (CML). It has been suggested that this chromosome abnormality is associated with special hematological characteristics of the BC, but the information on this subject is scarce. The clinical, hematological and cyt...

journal_title：Leukemia & lymphoma

authors： Hernández-Boluda JC,Cervantes F,Costa D,Carrió A,Montserrat E

更新日期：2000-06-01 00:00:00

abstract：:The combination of mitoxantrone (MIT), etoposide (ETP), and cytarabine (Ara-C) (MEC) is a frequently used salvage therapy for acute leukemia, but has been associated with severe myelosuppression. Therefore, we investigated the miniMEC regimen with reduced doses of AraC and MIT. Thirteen ALL and 44 AML patients, all re...

journal_title：Leukemia & lymphoma

authors： Yamamoto C,Ito S,Mashima K,Umino K,Minakata D,Yamasaki R,Kawasaki Y,Sugimoto M,Nakano H,Ashizawa M,Okazuka K,Hatano K,Sato K,Oh I,Fujiwara S,Ohmine K,Suzuki T,Muroi K,Kanda Y

更新日期：2016-11-01 00:00:00

abstract：:Preclinical studies suggest that bortezomib, through inhibition of nuclear factor-κB (NF-κB) activation, may enhance the effects of radioimmunotherapy. This phase I trial was designed to determine the maximum tolerated dose (MTD) of weekly bortezomib induction combined with Y-90-ibritumomab tiuxetan followed at the ti...

journal_title：Leukemia & lymphoma

authors： Roy R,Evens AM,Patton D,Gallot L,Larson A,Rademaker A,Cilley J,Spies S,Variakojis D,Gordon LI,Winter JN

更新日期：2013-03-01 00:00:00

abstract：:We and others previously demonstrated that human multiple myeloma (MM) cells express CD40 and have an active CD40-growth regulatory pathway. This study characterizes the growth outcome of soluble (gp39) or membrane-bound recombinant human CD40-ligand (rCD40L) and its relationship with Fas-dependent apoptosis. Contrary...

journal_title：Leukemia & lymphoma

authors： Tong AW,Seamour B,Chen J,Su D,Ordonez G,Frase L,Netto G,Stone MJ

更新日期：2000-02-01 00:00:00

abstract：:A rapid increase in incidence of non-Hodgkin lymphoma (NHL) has been reported from many countries. Exposure to certain pesticides and organochlorines has been shown to be risk factors. Epstein-Barr virus (EBV) is a human herpesvirus that has been associated with some subgroups of NHL, such as Burkitt lymphoma and lymp...

journal_title：Leukemia & lymphoma

authors： Hardell E,Eriksson M,Lindström G,Van Bavel B,Linde A,Carlberg M,Liljegren G

更新日期：2001-08-01 00:00:00

abstract：:We evaluated the safety and biologic activity of the BH3 mimetic protein, navitoclax, combined with rituximab, in comparison to rituximab alone. One hundred and eighteen patients with chronic lymphocytic leukemia (CLL) were randomized to receive eight weekly doses of rituximab (arm A), eight weekly doses of rituximab ...

journal_title：Leukemia & lymphoma

authors： Kipps TJ,Eradat H,Grosicki S,Catalano J,Cosolo W,Dyagil IS,Yalamanchili S,Chai A,Sahasranaman S,Punnoose E,Hurst D,Pylypenko H

更新日期：2015-01-01 00:00:00

abstract：:CD95 (Fas/Apo-1) mediates apoptosis in cells of various types. Expression of CD95 and its function were investigated in myeloma cells and most plasma cell lines have been found to be CD95-positive. Anti-CD95 antibody induced apoptosis in these cell lines in a manner dependent on intensity of CD95 expression. Bel-2 exp...

journal_title：Leukemia & lymphoma

authors： Hata H,Matsuzaki H,Takeya M,Takatsuki K

更新日期：1996-12-01 00:00:00

abstract：:The proliferation index in mantle cell lymphoma (MCL) has not been validated in the context of aggressive therapy regimens in the rituximab era. We assessed Ki67 and PIM1 (a cell cycle-related gene upregulated in blastoid MCL) expression by immunohistochemistry in a phase II study Cancer and Leukemia Group B 59909 of ...

journal_title：Leukemia & lymphoma

authors： Hsi ED,Jung SH,Lai R,Johnson JL,Cook JR,Jones D,Devos S,Cheson BD,Damon LE,Said J

更新日期：2008-11-01 00:00:00

abstract：:Respiratory viral pathogens are a common cause of morbidity in patients with hematologic malignancies. Sensitive molecular assays have increased the detection of common respiratory viruses and expanded the panel of detectable viruses. Both a rapid viral culture with direct fluorescence antibody (DFA) staining and a PC...

journal_title：Leukemia & lymphoma

authors： Murali S,Langston AA,Nolte FS,Banks G,Martin R,Caliendo AM

更新日期：2009-04-01 00:00:00

abstract：:The risk for opportunistic infections is correlated with low CD4+ T lymphocyte counts in patients with HIV. We performed a retrospective analysis in 54 patients with multiple myeloma undergoing high-dose melphalan chemotherapy + autologous peripheral blood stem cell transplantation to better define the value of routin...

journal_title：Leukemia & lymphoma

authors： Gorschlüter M,Glasmacher A,Sarazin S,Hackbarth F,Hoebert E,Orlopp K,Schmidt-Wolf IG,Mey U

更新日期：2007-03-01 00:00:00

abstract：:Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents. Although patients with laparotomy-staged disease without B symptoms or large mediastinal masses hav...

journal_title：Leukemia & lymphoma

authors： Hagemeister FB

更新日期：1993-01-01 00:00:00

abstract：:One of the possible causes of treatment failure in acute leukemia is the emergence of multidrug resistance caused by P-glycoprotein (P-gp) overexpression. We compared a flow cytometric assay using JC-1 with a technique using rhodamine 123 (rho123) to evaluate the P-gp function in acute leukemia. Samples from 50 acute ...

journal_title：Leukemia & lymphoma

authors： Swerts K,de Moerloose B,Dhooge C,Noens L,Laureys G,Benoit Y,Philippé J

更新日期：2004-11-01 00:00:00

abstract：:Familial hemophagocytic lymphohistiocytosis (FHL) is a rare and fatal disease of early childhood characterized by a non-malignant accumulation of activated T lymphocytes and histiocytes in the reticuloendothelial system. Moreover, immune system derangement, with prominent hypercytokinemia and low or absent cytotoxic T...

journal_title：Leukemia & lymphoma

authors： Fadeel B,Orrenius S,Henter JI

更新日期：2001-06-01 00:00:00

abstract：:Existing prognostic tools for HIV + diffuse large B-cell lymphoma (DLBCL) fail to accurately predict patient outcomes. To develop a novel prognostic algorithm incorporating molecular tumor characteristics and HIV disease factors, we included 80 patients with HIV-related DLBCL diagnosed between 1996 and 2007. Immunohis...

journal_title：Leukemia & lymphoma

authors： Chao C,Silverberg MJ,Chen LH,Xu L,Martínez-Maza O,Abrams DI,Zha HD,Haque R,Said J

更新日期：2018-02-01 00:00:00

abstract：:Current chemoimmunotherapy is unable to cure up to 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL). Targeting the mechanisms by which DLBCL evades apoptosis is crucial to overcoming treatment failure in this heterogeneous disease as both current and novel treatments depend on the apoptosis of mali...

journal_title：Leukemia & lymphoma

authors： Gifford G,Stevenson W,Best G

更新日期：2020-12-01 00:00:00

abstract：:Bryostatin, a macrocyclic lactone and protein kinase C (PKC) modulator, has been shown to have differentiation and anti-tumor activity against several leukemia cell lines in vitro. In this study, we demonstrated Bryostatin-induced differentiation in B-cell chronic lymphocytic leukemia (B-CLL) cells, characterized by a...

journal_title：Leukemia & lymphoma

authors： Thomas A,Pepper C,Hoy T,Bentley P

更新日期：2004-05-01 00:00:00

abstract：:NK/T-cell lymphoma is difficult to diagnose because there is no characteristic cytology to help the diagnosis in tissue sections, particularly when there is polymorphic cellular infiltration in the early stage of the disease. However, the nasal type of extranodal NK/T-cell lymphoma has a characteristic histologic patt...

journal_title：Leukemia & lymphoma

authors： Jia H,Sun T

更新日期：2004-07-01 00:00:00

abstract：:Composite lymphomas constitute the presence of two different types of non-Hodgkin lymphoma or Hodgkin and non-Hodgkin lymphoma at the same anatomic site. We report an unusual case of a 73-year-old woman who initially presented with a composite lymphoma of chronic lymphocytic leukemia (CLL) and follicular lymphoma. Aft...

journal_title：Leukemia & lymphoma

authors： Copur MS,Ledakis P,Novinski D,Fu K,Hutchins M,Frankforter S,Mleczko K,Sanger WG,Chan WC

更新日期：2004-05-01 00:00:00

abstract：:The purpose of this study was to explore lymphocyte subsets of newly diagnosed DLBCL patients, and dynamics along with treatment of R-CHOP. A total of 40 DLBCL patients were enrolled. ALC of grade III-IV DLBCL patients was significantly lower than that of health controls (1.33*10E9/L vs 1.89*10E9/L, p = 0.003), mostly...

journal_title：Leukemia & lymphoma

authors： Yang Z,Yu W,Wang S,Zhou X,Liu S,Ma S

更新日期：2019-12-01 00:00:00